Wealth Management Partners LLC Buys 14,533 Shares of Global X Genomics & Biotechnology ETF $GNOM

Wealth Management Partners LLC lifted its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 143.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,677 shares of the company’s stock after purchasing an additional 14,533 shares during the quarter. Wealth Management Partners LLC owned about 1.54% of Global X Genomics & Biotechnology ETF worth $1,739,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in GNOM. Halbert Hargrove Global Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF in the 3rd quarter valued at about $77,000. Farther Finance Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $257,000. Polaris Financial Partners acquired a new position in Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $1,067,000. Finally, Bank of America Corp DE boosted its holdings in Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after acquiring an additional 48,394 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ:GNOM opened at $68.72 on Thursday. Global X Genomics & Biotechnology ETF has a 52-week low of $41.16 and a 52-week high of $74.19. The business’s 50 day simple moving average is $65.91 and its two-hundred day simple moving average is $56.06. The firm has a market cap of $109.95 million, a P/E ratio of -29.37 and a beta of 1.17.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.